News & Updates
Filter by Specialty:
Antivirals underutilized after curative resection of HBV- or HCV-related HCC
Antiviral therapy is associated with substantial improvements in long-term overall survival (OS) but severely underutilized after curative hepatic resection in patients with hepatitis B virus (HBV)– or hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC), a real-world study involving predominantly Asian patients has shown.
Antivirals underutilized after curative resection of HBV- or HCV-related HCC
15 Jan 2024
Repotrectinib shows high response rates, durable activity in ROS1 fusion–positive NSCLC
The next-generation ROS1 and TRK tyrosine kinase inhibitor (TKI) repotrectinib has demonstrated high response rates and durable activity in patients with ROS1 fusion–positive non-small-cell lung cancer (NSCLC), regardless of whether they have previously received ROS1 TKI therapy, according to phase II results of the ongoing registrational TRIDENT-1 trial.
Repotrectinib shows high response rates, durable activity in ROS1 fusion–positive NSCLC
15 Jan 2024
Resection plus chemo improves survival in patients with UCR-MAC-LM
Primary tumour resection (PTR) in combination with chemotherapy (C) appears beneficial to a specific subgroup of patients with unresectable colorectal mucinous adenocarcinoma with liver metastasis (UCR-MAC-LM) compared with PTR or C alone, suggests a study.
Resection plus chemo improves survival in patients with UCR-MAC-LM
14 Jan 2024
Voice-based AI makes insulin management a breeze for T2D patients
A voice-based conversational artificial intelligence application helps type 2 diabetes (T2D) patients navigate basal insulin titration at home and, in turn, achieve rapid glycaemic control, as reported in a study.